ABOLOGIX founded in Geneva, Switzerland

Abologix was launched today, and it is the newest addition to the biotechnology ecosystem in the city of Geneva (Switzerland).

Dr. Ignacio Faus has been named Chairman of the Board of the company. He has more than 20+ years of experience in the pharmaceutical and biotechnology industries, in companies both in the USA and in Europe.

Abologix is a pre-clinical stage biopharmaceutical company developing best-in-class monoclonal antibodies by blocking the Junction Adhesion Molecule JAM-C and the extracellular matrix-related protein Olfactomedin-like protein 3 (Olfml3) for the treatment of hematological and solid cancers. The company is based in Geneva (Switzerland) and it is a spin-out from the laboratories of Profs. Beat Imhof and Thomas Matthes at the University of Genevaand the Hôpitaux Universitaires de Genève.